Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Moodys
Colorcon
Daiichi Sankyo
Cantor Fitzgerald
Merck
AstraZeneca
Dow
Fish and Richardson

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,785,403

« Back to Dashboard

Summary for Patent: 8,785,403
Title:Glucopyranoside compound
Abstract: A compound of the formula: ##STR00001## wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is --(CH.sub.2).sub.n-- (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
Inventor(s): Nomura; Sumihiro (Kawaguchi, JP), Kawanishi; Eiji (Kitamoto, JP), Ueta; Kiichiro (Wako, JP)
Assignee: Mitsubishi Tanabe Pharma Corporation (Osaka-Shi, JP)
Application Number:13/494,602
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,785,403

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-002 Sep 20, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-001 Sep 20, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-004 Sep 20, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-003 Sep 20, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Pharms INVOKAMET canagliflozin; metformin hydrochloride TABLET;ORAL 204353-001 Aug 8, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Pharms INVOKAMET canagliflozin; metformin hydrochloride TABLET;ORAL 204353-002 Aug 8, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Pharms INVOKAMET canagliflozin; metformin hydrochloride TABLET;ORAL 204353-003 Aug 8, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Pharms INVOKAMET canagliflozin; metformin hydrochloride TABLET;ORAL 204353-004 Aug 8, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,785,403

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,816,331 Substituted indazole-O-glucosides ➤ Subscribe
8,202,984 Glucopyranoside compound ➤ Subscribe
7,816,328 Substituted fused heterocyclic C-glycosides ➤ Subscribe
7,084,124 Substituted indazole-O-glucosides ➤ Subscribe
7,943,788 Glucopyranoside compound ➤ Subscribe
7,511,021 Substituted indazole-O-glucosides ➤ Subscribe
8,222,219 Glucopyranoside compound ➤ Subscribe
7,482,330 Substituted fused heterocyclic C-glycosides ➤ Subscribe
7,521,430 N-glucoside compounds having an inhibitory activity against sodium-dependent glucose transporter ➤ Subscribe
7,820,630 Substituted indole-O-glucosides ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,785,403

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 045173 ➤ Subscribe
Argentina 048282 ➤ Subscribe
Argentina 048375 ➤ Subscribe
Argentina 048376 ➤ Subscribe
Argentina 048377 ➤ Subscribe
Argentina 053329 ➤ Subscribe
Australia 2004260760 ➤ Subscribe
Australia 2004260761 ➤ Subscribe
Australia 2004261264 ➤ Subscribe
Australia 2004261660 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Cipla
Argus Health
Accenture
Harvard Business School
Daiichi Sankyo
AstraZeneca
Novartis
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot